2. The drug behind Europe's most valuable com...

Is Wayve the start-up that could at last be a British global AI giant? Why does its boss Alex Kendall think the UK is the best place to grow a tech business? How soon will most of us be riding in driverless taxis and cars? Robert talks to the founder and chief executive of Wayve, ...  Show more

Is a Smorgasbord of tax rises the best way to raise money? Should the capital gains tax rate be aligned with income tax? What about increased taxes on banks? Dan Neidle is back to tell Robert and Steph what he’d do in the upcoming Budget. Plus, how Reeves was punished by the ONS’ ...  Show more

Weight-loss drugs have become a golden formula for pharma growth. In this episode we speak to Sector Advisor Maria Latorre and Senior Economist Michaela Grimm about how GLP-1 treatments like Ozempic and Wegovy are reshaping the industry, and the risks that lie ahead. SHOWNOTES: • ...  Show more

Episode 601: Sam Parr ( https://twitter.com/theSamParr ) and Shaan Puri ( https://twitter.com/ShaanVP ) talk to Calley Means ( https://x.com/calleymeans ) about the $50T drug that has Americans in a chokehold.  — Show Notes: (0:00) Intro  (1:54) The problem with Ozempic (4:25) A ...  Show more

More than 1bn people around the world are obese. That means there should be extraordinary demand for drugs to cure or mitigate the condition. Novo Nordisk is now Europe’s most valuable company and Eli Lilly’s market value has more than doubled. Both make the “miracle” drugs th ...

More than 1bn people around the world are obese. That means there should be extraordinary demand for drugs to cure or mitigate the condition. Novo Nordisk is now Europe’s most valuable company and Eli Lilly’s market value has more than doubled. Both make the “miracle” drugs that ...  Show more